Our previous body of work showing that HDACi's act at least in part through the rescue of TGFβ receptor I and II expression and TGFβ tumor suppressor activity in a wide variety of cancer cells indicates the clinical potential of this concept. The gene discussed is TGFB1; the disease is neoplasm.